¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ Ä¡·á ½ÃÀå, ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2024-2032³â)
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
»óǰÄÚµå : 1573914
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 168 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¹ßÀÛ¼º ¾ß°£ Ç÷»ö¼Ò´¢Áõ(PNH) Ä¡·á ½ÃÀåÀº 2023³â 39¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 11.2%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

PNHÀÇ À¯º´·ü Áõ°¡°¡ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, Àü¹®ÀûÀÎ Áø´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î º¸´Ù ºü¸£°í Á¤È®ÇÑ Áø´ÜÀÌ ¿ëÀÌÇØÁ® Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ±ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ±× °á°ú, Áø´Ü ±â¼úÀÇ ¹ßÀü°ú PNH¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Ä¡·á ¿É¼ÇÀÇ °³¼±°ú ÇÔ²² PNH ȯÀÚÀÇ ±â´ë ¼ö¸íÀÌ ¿¬ÀåµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â´ë¼ö¸í ¿¬ÀåÀº Àå±âÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇÏ¿© ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼¼°è PNH Ä¡·á ½ÃÀåÀº º¸Ã¼ ¾ïÁ¦Á¦, öºÐ ¿ä¹ý, ¸é¿ª ¾ïÁ¦Á¦, °ñ¼ö ÀÌ½Ä ¹× ±âŸ ¹æ¹ýÀ¸·Î ºÐ·ùµÇ¸ç, 2023³â º¸Ã¼ ¾ïÁ¦Á¦ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ¿© 14¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ±â·ÏÇß½À´Ï´Ù. ¿¡Å¬¸®ÁÖ¸¿°ú ¶óºê¸±ÁÖ¸¿À» Æ÷ÇÔÇÑ º¸Ã¼ ¾ïÁ¦Á¦´Â ¿ëÇ÷À» ¾ïÁ¦Çϰí Ç÷ÀüÀ» Â÷´ÜÇϸç PNH ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â °ÍÀ¸·Î ÀÔÁõµÆ½À´Ï´Ù. ÀÌ·¯ÇÑ ¸Å·ÂÀûÀÎ ÀÓ»ó °á°ú´Â ÀÌµé ¾à¹°ÀÇ Ã¤Åà Ȯ´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖÀ¸¸ç, ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. º¸Ã¼ ¾ïÁ¦¿¡ ´ëÇÑ ¿¬±¸ÀÇ ¹ßÀüÀ¸·Î Åõ¿© Ƚ¼ö, ¾àµ¿ÇÐ, ȯÀÚ ¼øÀÀµµ°¡ °³¼±µÈ Â÷¼¼´ë ¾ïÁ¦Á¦°¡ °³¹ßµÇ°í ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¼¼°è PNH Ä¡·á ½ÃÀåÀº °æ±¸ Åõ¿©¿Í ºñ°æ±¸ Åõ¿©·Î ±¸ºÐµÇ¸ç, 2023³â¿¡´Â ºñ°æ±¸ Åõ¿© °æ·Î°¡ 58.5%ÀÇ ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Á¤¸Æ Åõ¿©´Â ¾à¹°ÀÌ Áï½Ã Ç÷·ù¿¡ µé¾î°¡ ±Þ¼º PNH ¿¡ÇǼҵ忡 ´ëóÇϱâ À§ÇØ ¾à¹°ÀÌ Áï½Ã Ç÷·ù¿¡ µé¾î°¡´Â °ÍÀ» º¸ÀåÇÏ´Â Áß¿äÇÑ ¿ä¼ÒÀÔ´Ï´Ù. Áֻ糪 Á¤¸ÆÀ¸·Î Åõ¿©µÇ´Â ¿¡Å©¸®ÁÖ¸¿À̳ª ¶óºê¸±ÁÖ¸¿°ú °°Àº ´ÜŬ·ÐÇ×ü´Â °æ±¸ Èí¼ö°¡ ³Ê¹« Å©°í ºÒ¾ÈÁ¤ÇÑ »ý¹°ÇÐÀû Á¦Á¦·Î¼­ ½ÃÀåÀÌ ºñ°æ±¸¿ë Á¦Á¦·Î ±â¿ï¾îÁö°í ÀÖ´Ù´Â °ÍÀ» µÞ¹ÞħÇÕ´Ï´Ù.

ºÏ¹Ì´Â 2023³â 46.6%ÀÇ Á¡À¯À²À» Â÷ÁöÇÏ¸ç ¼¼°è PNH Ä¡·á ½ÃÀå¿¡¼­ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù¿¡¼­´Â PNH¸¦ Æ÷ÇÔÇÑ Èñ±ÍÁúȯ Ä¡·á¿¡ ´ëÇØ À¯¸®ÇÑ »óȯ Á¤Ã¥À» ½ÃÇàÇϰí ÀÖ¾î ȯÀÚµéÀÇ °æÁ¦Àû ºÎ´ãÀ» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¤Ã¥Àº °í°¡ÀÇ Ä¡·áÁ¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿¡Å¬¸®ÁÖ¸¿(¼Ö¸®¸®½º), ¶óºê¸±ÁÖ¸¿(¿ïÆ®¶ó¸¶ºê) µî °í°¡ Ä¡·áÁ¦¿¡ ´ëÇÑ º¸Çè Àû¿ëÀº ȯÀÚµéÀÇ Ä¡·á ÀÇ¿åÀ» ´õ¿í ³ô¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ FDAÀÇ ÆÐ½ºÆ®Æ®·¢(Fast Track) ÁöÀ§ ¹× Èñ±ÍÁúȯ Ä¡·áÁ¦ ÁöÁ¤°ú °°Àº ±ÔÁ¦ ¸ÞÄ¿´ÏÁòÀº PNH Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ Èñ±ÍÁúȯ Ä¡·áÁ¦ÀÇ ½ÂÀÎÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ¯Çý´Â PNH Ä¡·áÁ¦ °³¹ß¿¡ ´ëÇÑ Á¦¾à ±â¾÷ÀÇ ÅõÀÚ¸¦ À¯Ä¡ÇÏ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï »óȲ

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Ä¡·á À¯Çüº°, 2021-2032³â

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ¿¬·ÉÃþº°, 2021-2032³â

Á¦8Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

Á¦9Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market was valued at USD 3.9 billion in 2023 and is projected to indicate a CAGR of 11.2% from 2024-2032. The rising prevalence of PNH is a primary driver of this market growth, leading to heightened demand for specialized diagnostic techniques. These advancements have facilitated earlier and more precise diagnoses, expanding the patient population in need of treatment. Consequently, as diagnostic techniques advance and awareness of PNH grows, coupled with improved treatment options, the life expectancy of PNH patients has risen. This uptick in life expectancy has resulted in a sustained demand for long-term treatment solutions, further propelling market growth.

The overall paroxysmal nocturnal hemoglobinuria (PNH) treatment industry is classified based on treatment type, route of administration, age group, end-use, and region.

The global PNH treatment market categorizes treatments into complement inhibitors, iron therapy, immunosuppressants, bone marrow transplants, and other methods. In 2023, the complement inhibitors segment led the market, generating revenues of USD 1.4 billion. Complement inhibitors, including eculizumab and ravulizumab, have proven effective in curbing hemolysis, thwarting blood clots, and enhancing the quality of life for PNH patients. These compelling clinical outcomes are fueling their rising adoption, thus bolstering market growth. Research advancements in complement inhibition have birthed next-gen inhibitors, boasting superior less frequent dosing, pharmacokinetics, and heightened patient compliance, all of which amplify market growth.

The global PNH treatment market distinguishes between oral and parenteral routes of administration. In 2023, the parenteral route commanded a dominant 58.5% market share. Intravenous administration ensures medications enter the bloodstream instantly, a crucial factor for addressing acute PNH episodes. Monoclonal antibodies like eculizumab and ravulizumab, administered via injections or infusions, are biologics too large and unstable for oral absorption, underscoring the market's tilt towards parenteral formulations.

North America, with a commanding 46.6% share in 2023, is poised to maintain its dominance in the global PNH treatment market. Favorable reimbursement policies in the U.S. and Canada for rare disease treatments, including PNH, alleviate financial burdens on patients. Such policies enhance accessibility to costly therapies. Insurance backing for premium drugs like eculizumab (Soliris) and ravulizumab (Ultomiris) further motivates patients to pursue treatment. Regulatory mechanisms like Fast Track status and Orphan Drug Designation by the U.S. FDA expedite approvals for rare disease drugs, including those for PNH. Such incentives attract pharmaceutical investments in PNH therapy development, accelerating market growth.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Million)

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

Chapter 10 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â